ImetelChat

hunting, have you checked out the MAIA startup? They're working on 6-thio-dG, the chemical favored by Dr. Shay in some 2015-2016 papers.

https://maiabiotech.com/our-pipeline/thio/

Dr. Rizo didn't "come to Geron". She left Janssen, presumably because she knew the imet project was shutting down, and went to CELG. Then Geron was forced to hire her as it had no one qualified to run a trial. There is nothing negative about that, but nothing positive either. She simply didn't have ...

Even for cancer prevention, and even in animals that don't turn off telomerase!

https://phys.org/news/2019-10-mice-born ... omeres.amp

Prevention trumps palliatives.

How darest thou sully the purity of the Cult with thine shameless seeking after mere food, shelter, and medical insurance! Only the highest of the high-born mayest have the honour of sacrificing their inheritance and substance into Geron. Begone before the Great Old One Rises for the next Call Of Ch...

https://seekingalpha.com/instablog/2368 ... veryone-go

Bridge confirms that GERN is withholding the Mayo data. Also that they are doing no work on improving imet or imet delivery systems.

Yes, the priests were horrified when smallpox vaccine let some children "unnaturally" live to adulthood, and they've moaned at every advance since. (Read about Ethan Allan's fight with the clergy on vaccination...) Since I was immortalizing cells with vectors in 2001, I think you're a little out of ...

Kara, Geron actually has at least one patent relating to 6-thio-G... this is just another issue that makes people who follow GERN lose SAN points. The specific MOAs of imet and 6-thio-G are very different, maybe they could be used in combo? With all the GERN patents, why is Scarlett constantly tryin...

>"MF may get approved based on historical data." Yes, that has always been a major hope here (maybe the principal hope, given the competition and timeline in MDS). But it can't happen before the company at least talks to the FDA in 2020. There is plenty of time to order a short oligo from a commerci...

I agree, this is somewhat encouraging. They probably don't have useful historical controls right now because of the differences between different hospitals' protocols and generally bad databases (HIPAA didn't help the already-backwards hospital medical databases). But that doesn't that the necessary...

I keep seeing posts on YHOO and Seeking Alpha from people that "can't get full text of X paper", or even "I can't post the abstract to this paper".

Sci-hub solved these problems long ago, here's the link:

https://whereisscihub.now.sh/

The issue with Janssen as an imetelstat supplier is cost, not quantity. Any commercial supplier would give a better deal (kind of nasty of Janssen to charge high prices for their stockpile of a drug that they are just discarding anyway, but there it is). Again, it's the medical organization "EHA", n...

So has anyone here read this?

You can bet that JNJ read the 2015 papers.

It's the EHA, not the EMA. One tries to cure heme diseases, the other protects pharma cartel profits... try to keep them straight ;) Yes, this is the best-case scenario. IF the abstract suggests durable effectiveness, and IF we hear from Rizo instead of having the entire presentation in stuttervisio...

kara, neither of the Phase 2 trials have placebo arms IIRC. They are using "historical controls", which are very poor as different hospitals keep records differently and the patient groups may not be comparable. The MF trial does have some comparison available between the two dose arms, as the low-d...

I'm all in favor of market-based CEO compensation. I remember the hilarity that ensued when Ben&Jerry tried to hire a "CEO" for one-tenth the market rate (they ended up paying the market rate after all, big surprise). But that doesn't mean that stockholders can just go to sleep while a long-term CEO...

This is a bit premature, but this is a 2018 paper on Phase 3 success rates broken down by category: https://academic.oup.com/biostatistics/article/20/2/273/4817524 Obviously Geron has some special factors (e.g. the large number of previous failed trials), but at least knowing the average success rat...

Thanks Smuggie, interesting stuff... I would have expected options to work better as incentives, at least on CEOs that are below retirement age and still have active lifespan remaining. The good news at GERN, if there is any, is that the Janssen crew knows more about the MOA than anyone else. That d...

@muskateer:

https://www.fda.gov/drugs/developmentap ... efault.htm